PARTNERS CAPITAL INVESTMENT GROUP, LLP - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.

Quarter-by-quarter ownership
PARTNERS CAPITAL INVESTMENT GROUP, LLP ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q2 2022$12,000
-14.3%
1,3710.0%0.00%0.0%
Q1 2022$14,000
-99.8%
1,371
-99.7%
0.00%
-99.7%
Q4 2021$8,079,000
-63.2%
484,373
+3.5%
0.37%
-62.8%
Q3 2021$21,941,000
-17.7%
468,128
+7.0%
1.00%
-15.3%
Q2 2021$26,667,000437,4541.19%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders